Subjective Experience and Dopamine D2 Receptor Occupancy in Patients Treated with Antipsychotics: Clinical Implications
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Objectives: This paper gives an overview of studies on the association between dopaminergic neurotransmission and the subjective experience of patients with schizophrenia. Methods: We undertook a review of the literature. Results: Dopaminergic neurotransmission may be relevant for subjective experience. Higher striatal D 2 receptor occupancy by typical and atypical antipsychotics is related to worse subjective experience, more severe negative symptoms, and depression. Individuals with lower baseline dopamine function are at an increased risk for dysphoric responses during antipsychotic therapy with dopaminergic-blocking drugs. There is preliminary evidence that a window of striatal D 2 receptor occupancy between 60% and 70% is optimal for the subjective experience of patients. These occupancies are often reached even with low dosages of antipsychotic drugs. Conclusions: Reaching an optimal dopamine D 2 receptor occupancy is clinically relevant, since subjective experience associated with antipsychotic medication is related to medication compliance. Antipsychotic drug dosages often need to be lower than levels in common use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience?
Berridge, K. C., & Robinson, T. E. (1998) · Brain Research Reviews · doi:10.1016/s0165-0173(98)00019-8 · Cited by 4,127
Kapur, S. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.1.13 · Cited by 2,813 · cited 3×
“A dysregulated hyperdopaminergic state at brain level leads to an aberrant assignment of salience to the elements of experience at mind level (13).”
InfluentialDrugs of abuse: anatomy, pharmacology and function of reward pathways
Koob, G. F. (1992) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(92)90060-j · Cited by 2,070
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
Kapur, S., Zipursky, R., Jones, C., Remington, G., & Houle, S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.514 · Cited by 1,090
Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs.
Pontieri, F. E., Tanda, G., Orzi, F., & Chiara, G. D. (1996) · Nature · doi:10.1038/382255a0 · Cited by 1,073 · cited 1×
“Nicotine stimulates the release of dopamine and the energy metabolism in the basal ganglia, especially in the ventral tegmental areas and the nucleus accumbens (28), putamen, and nucleus caudatus (29); this is probably the central reinforcing mechanism of addictive substances (30).”
Atypical antipsychotics: Mechanism of action
Seeman, P. (2002) · The Canadian Journal of Psychiatry · doi:10.1177/070674370204700106 · Cited by 899
(1998) · PubMed · doi:10.1176/ajp.155.3.344 · Cited by 784
The involvement of nucleus accumbens dopamine in appetitive and aversive motivation
Salamone, J. D. (1994) · Behavioural Brain Research · doi:10.1016/0166-4328(94)90153-8 · Cited by 584
Volkow, N. D., Wang, G.-J., Fowler, J. S., Logan, J., Gatley, S. J., Gifford, A., Hitzemann, R., Ding, Y.-S., & Pappas, N. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.9.1440 · Cited by 406 · cited 2×
“Too low levels may not be sufficient to induce a subjective “high,” but too high levels may have an aversive effect (34).”
Cited by
Juckel, G., Schlagenhauf, F., Koslowski, M., Filonov, D., Wüstenberg, T., Villringer, A., Knutson, B., Kienast, T., Gallinat, J., Wrase, J., et al. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0405-4 · Cited by 323
Reward system activation in schizophrenic patients switched from typical neuroleptics to olanzapine
Schlagenhauf, F., Juckel, G., Koslowski, M., Kahnt, T., Knutson, B., Dembler, T., Kienast, T., Gallinat, J., Wrase, J., & Heinz, A. (2008) · Psychopharmacology · doi:10.1007/s00213-007-1016-4 · Cited by 204
Barkhof, E., Meijer, C. J., de Sonneville, L. M. J., Linszen, D. H., & de Haan, L. (2012) · European Psychiatry · doi:10.1016/j.eurpsy.2011.02.005 · Cited by 183
Self-citationEstimating Dopamine D2 Receptor Occupancy for Doses of 8 Antipsychotics: A Meta-Analysis
Lako, I. M., van den Heuvel, E. R., Knegtering, H., Bruggeman, R., & Taxis, K. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182983ffa · Cited by 125
“For example, to optimize treatment strategies by finding thresholds of D2 receptor occupancy indicative for D2 receptorYmediated (adverse) effects.(14,28,29) This means that our functions can be used as an alternative to the conventional methods to determine equivalent doses of different antipsychotics, such as the de…”
MethodMoritz, S., Veckenstedt, R., Randjbar, S., Vitzthum, F., Karow, A., & Lincoln, T. M. (2010) · Psychosis · doi:10.1080/17522430903191791 · Cited by 51
“In line with studies conducted by our group (Krausz, Moritz, Lambert, & Naber, 2000) as well as other researchers (de Haan et al., 2004) we found a modest linear relationship between neuroleptic dosage and low selfesteem which persisted after controlling for overall psychopathology.”
Result
Metadata
- Authors
- de Haan, L., Lavalaye, J., van Bruggen, M., van Nimwegen, L., Booij, J., van Amelsvoort, T., & Linszen, D.
- Venue
- The Canadian Journal of Psychiatry
- Publisher
- SAGE Publications
- Published
- 2004-05
- Volume
- 49
- Issue
- 5
- Pages
- 290-296
- ISSN
- 0706-7437 (ISSN-L)
- 1497-0015
- OpenAlex
- W1492008158
- Cited by
- 68
- References
- 14
- FWCI
- 3.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Subjective Experience and Dopamine D2 Receptor Occupancy in Patients Treated with Antipsychotics: Clinical Implications. https://app.cochat.ai/papers/10.1177/070674370404900503
- The paper
- de Haan, L., Lavalaye, J., van Bruggen, M., van Nimwegen, L., Booij, J., van Amelsvoort, T., & Linszen, D. (2004). Subjective Experience and Dopamine D2 Receptor Occupancy in Patients Treated with Antipsychotics: Clinical Implications. The Canadian Journal of Psychiatry. https://doi.org/10.1177/070674370404900503
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.